Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569212 | 0.82 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827673 | 0.79 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827784 | 0.78 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827732 | 0.76 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19185300 | 0.74 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20782409 | 0.73 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827757 | 0.73 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20072408 | 0.71 | CHEK1 (0.47) | — | |
| SCHEMBL21388659 | 0.71 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14024537 | 0.68 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259818-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-9944646-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259818-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CB | PI4KA 10/4885PI4K2B 14/4885PI4K2A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.